BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$80.91 USD
-1.26 (-1.53%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $80.92 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Income Statements
Fiscal Year end for BioMarin Pharmaceutical Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,419 | 2,096 | 1,846 | 1,860 | 1,704 |
Cost Of Goods | 515 | 484 | 471 | 524 | 359 |
Gross Profit | 1,904 | 1,612 | 1,376 | 1,336 | 1,345 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,746 | 1,463 | 1,458 | 1,373 | 1,445 |
Income After Depreciation & Amortization | 158 | 150 | -82 | -37 | -100 |
Non-Operating Income | 48 | 16 | 22 | 24 | 29 |
Interest Expense | 17 | 16 | 15 | 29 | 23 |
Pretax Income | 189 | 150 | -75 | -42 | -95 |
Income Taxes | 21 | 8 | -11 | -901 | -71 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 168 | 142 | -64 | 859 | -24 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 168 | 142 | -64 | 859 | -24 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 253 | 255 | 31 | 69 | 3 |
Depreciation & Amortization (Cash Flow) | 95 | 105 | 113 | 106 | 103 |
Income After Depreciation & Amortization | 158 | 150 | -82 | -37 | -100 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 191.60 | 188.96 | 182.85 | 191.68 | 179.04 |
Diluted EPS Before Non-Recurring Items | 1.23 | 0.89 | 0.25 | 0.68 | 0.07 |
Diluted Net EPS (GAAP) | 0.87 | 0.75 | -0.35 | 4.53 | -0.13 |
Fiscal Year end for BioMarin Pharmaceutical Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 646.21 | 581.33 | 595.28 | 596.42 |
Cost Of Goods | NA | 135.48 | 124.75 | 128.08 | 126.55 |
Gross Profit | NA | 510.73 | 456.58 | 467.19 | 469.87 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 434.29 | 430.92 | 408.32 | 410.52 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 76.44 | 25.66 | 58.87 | 59.35 |
Non-Operating Income | NA | 11.21 | 19.79 | 15.70 | 1.11 |
Interest Expense | NA | 6.10 | 3.78 | 3.76 | 3.70 |
Pretax Income | NA | 19.33 | 41.67 | 70.81 | 56.76 |
Income Taxes | NA | -1.05 | 1.29 | 14.77 | 5.91 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 20.38 | 40.38 | 56.04 | 50.85 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 20.38 | 40.38 | 56.04 | 50.85 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 191.84 | 191.17 | 195.00 | 194.36 |
Diluted EPS Before Non-Recurring Items | NA | 0.26 | 0.26 | 0.34 | 0.39 |
Diluted Net EPS (GAAP) | NA | 0.10 | 0.21 | 0.29 | 0.27 |